Screener
Rigel Pharmaceuticals RIGL Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 30,651 | 27,715 |
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
| Interest income | 1,205 | 591 |
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's interest income?
- Rigel Pharmaceuticals (RIGL) reported interest income of $1.21M in Q1 2026.
- How has Rigel Pharmaceuticals's interest income changed year-over-year?
- Rigel Pharmaceuticals's interest income increased by 103.9% year-over-year, from $591K to $1.21M.
- What is the long-term trend for Rigel Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's interest income has grown at a 197.5% compound annual growth rate (CAGR), from $47K to $3.68M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Rigel Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude